Back to results
US 2019/0194348 A1Published application
Treatment of therapy-resistant her-2 positive breast cancer
OwnerShiuh-Wen Luohinventor
Life of this patent
Estimating the term…
Abstract
This invention concerns the treatment of HER-2 positive breast cancer cells by mediating the signal of GRB7 using an anti-HER-1 antibody, such as panitumumab.
Claims18
A method of treatment for therapy-resistant HER-2 positive breast cancer in a human, the method comprising administering to a human in need thereof a pharmaceutically effective amount of an anti-HER-1 antibody.
A method of treating HER-2 positive breast cancer in a human, the method comprising administering to a human in need thereof:
- g) a pharmaceutically effective amount of panitumumab;
- h) a pharmaceutically effective amount of trastuzumab;
- and
- i) a pharmaceutically effective amount of at least one inhibitor of the HER receptor family selected from the group of lapatinib, neratinib, and afatinib, tor a pharmaceutically acceptable salt thereof.
1 more element
A method of treatment for therapy-resistant HER-2 positive breast cancer in a human, the method comprising administering to a human in need thereof
- a) a pharmaceutically effective amount of an anti-HER-1 antibody;
- b) a pharmaceutically effective amount of a second agent selected from an anti-HER-2 antibody and a toxin-conjugated anti-HER-2 antibody;
- and
- c) a pharmaceutically effective amount of an anti-HER tyrosine kinase inhibitor.
1 more element
Dependencies are inferred from the claim text.